Business context and reporting period
This is StemCells, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014—not a filing for Microbot Medical Inc., as indicated in the request metadata. StemCells was a biopharmaceutical company developing stem-cell therapeutics and research products. Its lead HuCNS-SC program was in clinical development for chronic spinal cord injury, dry age-related macular degeneration (AMD), and Pelizaeus-Merzbacher disease; Alzheimer’s disease work was preclinical.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 / prior date |
|---|---|---|
| Revenue | $339,480 | $284,200 |
| Gross profit | $252,204; approximately 74% gross margin | $217,359 |
| Operating expenses | $7.15 million | $6.47 million |
| Operating loss | $6.90 million | $6.26 million |
| Net loss | $7.62 million; $0.14 per share | $6.42 million; $0.17 per share |
| Cash used in operations | $6.51 million | $6.65 million |
| Cash and cash equivalents | $26.46 million | $30.59 million at Dec. 31, 2013 |
| Total assets / liabilities | $36.83 million / $29.17 million | $41.56 million / $26.60 million at Dec. 31, 2013 |
Product-sales revenue rose 51% to $315,896, mainly on increased SC Proven media and reagent volumes. Licensing, grants, and other revenue declined 69% to $23,584. R&D expense increased 7% to $4.90 million, principally with higher clinical-study and personnel costs; SG&A increased 19% to $2.25 million, including higher legal, recruiting, and payroll costs. Other expense was $721,000, including $380,000 interest expense and a $327,000 warrant-liability fair-value loss.
Current assets were $27.21 million and current liabilities $8.37 million at quarter-end. Loan payable, net of discount, was $15.84 million, including $3.75 million current; bonds payable were $71,250 and capital-lease obligations totaled approximately $45,600. Cash fell $4.12 million during the quarter. Financing cash flow included $3.82 million of CIRM loan proceeds; investing cash flow was a $231,000 use, mainly for lab equipment.
Material changes, outlook, and risks
- Net loss widened year over year despite higher revenue; weighted-average shares rose to 55.34 million from 38.26 million, so reported loss per share was lower at $0.14 versus $0.17.
- StemCells said it had incurred significant losses since inception, expected further losses, did not expect profitability in the next several years, and needed significant additional capital. It warned that if financing were unavailable after cash reserves were exhausted, it might be unable to meet obligations and could be required to initiate bankruptcy proceedings. The filing provides no specific cash-runway estimate.
- The company had an effective shelf registration permitting up to $100 million of registered debt and equity securities, but future funding availability and terms were uncertain. The SVB loan carried 6% annual interest and a final $1 million fee; the CIRM agreement provided for up to approximately $19.3 million in a conditional, potentially forgivable loan. CIRM had disbursed approximately $3.8 million in January 2014.
- Management reported completing enrollment of the first eight-patient dry AMD cohort in February and expected to enroll the second eight-patient cohort by the end of Q2 2014. The final patient in the 12-person spinal-cord-injury Phase I/II study was enrolled in April; results were expected mid-2015. A controlled Phase II spinal-cord-injury study was planned for mid-2014.
- Key risks included clinical safety and efficacy, regulatory uncertainty, trial delays and costs, need for financing or partners, manufacturing, competition, and patent validity and litigation. Neuralstem litigation remained ongoing with discovery in progress; the European patent appeal described in the filing had been withdrawn with prejudice. The company reported no material change in the risk factors from its 2013 Form 10-K.
- Outstanding potential dilution included 3.14 million restricted stock units and 8.12 million Series A warrants; the warrant liability was $5.87 million and subject to model-based fair-value changes.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is StemCells, Inc., not Microbot Medical Inc.
- Review subsequent financing, cash burn, and debt-service developments against the company’s explicit warning of limited liquidity and potential inability to continue operations without capital.
- Check progress and reported outcomes for the spinal cord injury and AMD trials, including whether planned timelines and regulatory steps were achieved.
- Verify CIRM disbursement conditions, loan forgiveness and repayment terms, and the schedule and obligations of the SVB loan.
- Assess potential dilution, warrant remeasurement effects, and developments in the Neuralstem litigation.